StreetInsider.com News Articles

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.’s oldest and most prestigious science and math competition for high school seniors.

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc

Tue, 10 Mar 2026 21:29:00 -0400

Key Takeaways:

This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10th year as the title sponsor; Regeneron is

Regeneron Pharma (REGN) PT Raised to $890 at Jefferies

Tue, 10 Mar 2026 17:06:39 -0400

Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $890.00 (from $885.00) while maintaining a Buy rating.

The analyst commented, "REGN toplined Ph.3 GLP/GIP China data - olatorepatide showed up to 19% WL which looks similar to 10mg tirze at 48wks & safety looks good w/ <10% nausea & <5% vomiting. To us, we think there's room to dose higher, given solid tolerability. Most impt'ly, we think the Street is underappreciating REGN's opportunity in obesity & combination w/ PCSK9 - cons attributes only ~$285M peak revs despite plans to start global Ph.3 in obesity & Ph.3

Regeneron Pharma (REGN) PT Raised to $890 at Jefferies

Tue, 10 Mar 2026 17:06:39 -0400

Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $890.00 (from $885.00) while maintaining a Buy rating.

TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN): "if results are replicated in US, could lead to preferential prescribing"

Mon, 09 Mar 2026 09:59:23 -0400

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $880.00 price target on Regeneron Pharma (NASDAQ: REGN)

The analyst commented, "Regeneron and Hansoh reported 48-week Phase III data of olatorepatide (5mg, 10mg, and 15mg) in Chinese obesity patients. Ola led to an up to 19% mean weight loss from baseline at week 48 with up to 97% of patients achieving a >5% weight loss. These results are relatively in-line with other GLP-1/GIPs including tirzepatide, which demonstrated an estimated 20% weight loss from baseline at week 48. Regarding the safety and tolerability profile, ola's average incidence of nausea was below

Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results

Mon, 09 Mar 2026 09:41:51 -0400

Truist Securities analyst Greg Renza reiterated a Buy rating and $818.00 price target on Regeneron Pharma (NASDAQ: REGN)

The analyst commented, "This morning, REGN shared topline results from a ph.III study of olatorepatide (ola'; dual GLP-1/GIPR agonist) for the treatment of adults with obesity or who are overweight, conducted by Hansoh (3692.HK, NR) in China. Ola' (QW) demonstrated a 19% in mean weight loss, with statistical significance, from baseline at wk 48, with appreciable tolerability versus the incretin class, in our view, with the average incidence of nausea <10% and vomiting <5%. We look ahead to more detailed data at a

Regeneron obesity drug shows 19% weight loss in phase 3 trial

Mon, 09 Mar 2026 07:00:32 -0400

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that partner Hansoh Pharmaceutical Group Company Limited reported positive results from a Phase 3 trial of olatorepatide, an obesity treatment, in Chinese patients.

The randomized, double-blind, placebo-controlled trial enrolled 604 adults across 33 clinical sites in mainland China and evaluated once-weekly olatorepatide compared to placebo for 48 weeks. The study assessed four cohorts with 5 mg, 10 mg, 15 mg olatorepatide doses and placebo.

Participants treated with olatorepatide achieved up to 19% mean weight loss from baseline at week 48. The trial met its co-primary endpoints, showing statistically significant reduction in body weight compared to placebo

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Mon, 09 Mar 2026 07:00:00 -0400

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48

Regeneron’s global Phase 3 registrational program to be initiated later this year

TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepatide is a novel dual GLP-1/GIP receptor agonist for which Regeneron has exclusive clinical development and commercial rights outside of the Chinese

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Mon, 09 Mar 2026 07:00:00 -0400

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48

Regeneron’s global Phase 3 registrational program to be initiated later this year

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Mon, 09 Mar 2026 07:00:00 -0400

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48

Regeneron’s global Phase 3 registrational program to be initiated later this year

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Mon, 09 Mar 2026 07:00:00 -0400

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48

Regeneron’s global Phase 3 registrational program to be initiated later this year

Barclays Starts Regeneron Pharma (REGN) at Overweight

Fri, 06 Mar 2026 02:51:30 -0400

Barclays analyst Eliana Merle initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Overweight rating and a price target of $923.00.

The analyst comments: "We initiate coverage of REGN with an Overweight rating and a $923 price target. We see Dupixent indication expansion as an underappreciated tailwind, for a product with sizable operating leverage. While there exist headwinds for the Eylea franchise, we expect REGN's overall portfolio growth outpaces this. We see top & bottom line beats ahead as well as a rich pipeline of readouts over the next 1-2 years to support upside. We see LAG3 as an important

Barclays Starts Regeneron Pharma (REGN) at Overweight

Fri, 06 Mar 2026 02:51:30 -0400

Barclays analyst Eliana Merle initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Overweight rating and a price target of $923.00.

Regeneron Announces Investor Conference Presentation

Thu, 05 Mar 2026 16:05:00 -0400

TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026.

The session may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and

Regeneron Announces Investor Conference Presentation

Thu, 05 Mar 2026 16:05:00 -0400

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Tue, 03 Mar 2026 17:31:00 -0400

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.

LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Tue, 03 Mar 2026 17:31:00 -0400

LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Tue, 03 Mar 2026 17:31:00 -0400

LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Tue, 03 Mar 2026 17:31:00 -0400

LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney